Is Viatris Stock Outperforming the S&P 500? Viatris has comfortably outperformed the broader S&P 500 over the past year, with analysts maintaining a fairly bullish outlook on the stock. Barchart · Sep 24
Is Wall Street Bullish or Bearish on Viatris Stock? Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects. Barchart · Aug 4
Viatris’ Quarterly Earnings Preview: What You Need to Know Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago. Barchart · Jul 22
Are Wall Street Analysts Bullish on Viatris Stock? Despite outperforming the broader market over the past year, Viatris continues to earn a cautiously optimistic outlook from Wall Street. Barchart · May 6
Viatris' Q1 2026 Earnings: What to Expect Viatris is set to announce its first-quarter earnings next month, and Wall Street expects the company’s EPS to increase by a single digit. Barchart · Apr 23
Viatris Stock: Is VTRS Outperforming the Health Care Sector? As Viatris has outperformed the broader health care sector over the past year, and analysts remain moderately optimistic about the stock’s prospects. Barchart · Mar 23
What Are Wall Street Analysts' Target Price for Viatris Stock? Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects. Barchart · Feb 2
Viatris Earnings Preview: What to Expect Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits. Barchart · Jan 22
Is Viatris Stock Outperforming the Dow? As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects. Barchart · Dec 15, 2025
Viatris Stock: Is Wall Street Bullish or Bearish? Viatris has underperformed the broader market in recent months, and analysts’ outlook remains guarded as the company executes on its transformation efforts. Barchart · Nov 4, 2025
What You Need to Know Ahead of Viatris' Earnings Release Viatris will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip. Barchart · Oct 24, 2025
Is Viatris Stock Underperforming the Nasdaq? Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains guarded. Barchart · Sep 26, 2025
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS In the latest investment moves, Greenlight Capital (NASDAQ:GLRE), led by David Einhorn, has disclosed its Q2 2025 13F filing trades. Benzinga · Aug 16, 2025
Viatris Stock: Analyst Estimates & Ratings Viatris has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects. Barchart · Aug 5, 2025
Barchart · Jul 23, 2025 What to Expect From Viatris' Next Quarterly Earnings Report Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.
Benzinga · Jul 18, 2025 Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.
Barchart · Jun 24, 2025 Is Viatris Stock Underperforming the S&P 500? Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.
Barchart · May 7, 2025 Do Wall Street Analysts Like Viatris Stock? Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.
Barchart · Apr 28, 2025 What to Expect From Viatris' Q1 2025 Earnings Report Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.
Barchart · Apr 1, 2025 How Is Viatris’ Stock Performance Compared to Other Biotech Stocks? Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.
Barchart · Feb 5, 2025 Viatris Stock Outlook: Is Wall Street Bullish or Bearish? As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.
StockNews.com · Jan 29, 2025 3 Hidden Bargains in the Healthcare Sector Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…
Barchart · Dec 26, 2024 Viatris Stock: Is VTRS Outperforming the Healthcare Sector? Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.
Barchart · Nov 6, 2024 Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink? Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.
Barchart · Oct 27, 2024 Earnings Preview: What to Expect From Viatris' Report Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.